1. Home
  2. VIGL vs EDAP Comparison

VIGL vs EDAP Comparison

Compare VIGL & EDAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VIGL
  • EDAP
  • Stock Information
  • Founded
  • VIGL 2020
  • EDAP 1979
  • Country
  • VIGL United States
  • EDAP France
  • Employees
  • VIGL N/A
  • EDAP N/A
  • Industry
  • VIGL Biotechnology: Pharmaceutical Preparations
  • EDAP Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • Sector
  • VIGL Health Care
  • EDAP Health Care
  • Exchange
  • VIGL Nasdaq
  • EDAP Nasdaq
  • Market Cap
  • VIGL 89.3M
  • EDAP 81.6M
  • IPO Year
  • VIGL 2022
  • EDAP 1997
  • Fundamental
  • Price
  • VIGL $2.73
  • EDAP $2.48
  • Analyst Decision
  • VIGL Strong Buy
  • EDAP Strong Buy
  • Analyst Count
  • VIGL 5
  • EDAP 1
  • Target Price
  • VIGL $21.00
  • EDAP $19.00
  • AVG Volume (30 Days)
  • VIGL 2.6M
  • EDAP 42.1K
  • Earning Date
  • VIGL 03-25-2025
  • EDAP 03-26-2025
  • Dividend Yield
  • VIGL N/A
  • EDAP N/A
  • EPS Growth
  • VIGL N/A
  • EDAP N/A
  • EPS
  • VIGL N/A
  • EDAP N/A
  • Revenue
  • VIGL N/A
  • EDAP $70,722,730.00
  • Revenue This Year
  • VIGL N/A
  • EDAP $6.96
  • Revenue Next Year
  • VIGL N/A
  • EDAP $15.53
  • P/E Ratio
  • VIGL N/A
  • EDAP N/A
  • Revenue Growth
  • VIGL N/A
  • EDAP 12.17
  • 52 Week Low
  • VIGL $1.49
  • EDAP $2.00
  • 52 Week High
  • VIGL $6.06
  • EDAP $8.50
  • Technical
  • Relative Strength Index (RSI)
  • VIGL 71.47
  • EDAP 58.86
  • Support Level
  • VIGL $2.22
  • EDAP $2.15
  • Resistance Level
  • VIGL $2.53
  • EDAP $2.57
  • Average True Range (ATR)
  • VIGL 0.29
  • EDAP 0.14
  • MACD
  • VIGL 0.08
  • EDAP 0.04
  • Stochastic Oscillator
  • VIGL 80.47
  • EDAP 79.55

About VIGL Vigil Neuroscience Inc.

Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.

About EDAP EDAP TMS S.A.

Edap TMS SA is a holding company operating in three divisions namely, HIFU (High-Intensity Focused Ultrasound), ESWL (Extracorporeal ShockWave Lithotripsy), and Distribution. The HIFU division develops, manufactures, and markets devices for the invasive destruction of certain types of tumors using HIFU technology. It markets three HIFU devices: the Ablatherm, Ablatherm Fusion, and the Focal One. The ESWL division is engaged in the manufacturing, marketing, and servicing of its installed base of Sonolith range of lithotripters. The Distribution division markets products that are complementary to its global activity such as lasers, micro-ultrasound systems, and other medical products from third parties. Its geographical segments are Asia, France, United States, and Others.

Share on Social Networks: